238 related articles for article (PubMed ID: 16856879)
1. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells.
Sasaki T; Ikeda H; Sato M; Ohkuri T; Abe H; Kuroki M; Onodera M; Miyamoto M; Kondo S; Nishimura T
Cancer Sci; 2006 Sep; 97(9):920-7. PubMed ID: 16856879
[TBL] [Abstract][Full Text] [Related]
2. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor.
Gyobu H; Tsuji T; Suzuki Y; Ohkuri T; Chamoto K; Kuroki M; Miyoshi H; Kawarada Y; Katoh H; Takeshima T; Nishimura T
Cancer Res; 2004 Feb; 64(4):1490-5. PubMed ID: 14973062
[TBL] [Abstract][Full Text] [Related]
3. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
4. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
5. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
6. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.
Simmons A; Whitehead RP; Kolokoltsov AA; Davey RA
Virol J; 2006 Feb; 3():8. PubMed ID: 16507098
[TBL] [Abstract][Full Text] [Related]
7. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
8. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E; Toutirais O; Tougeron D; Drouet A; Le Gallo M; Desille M; Cabillic F; de La Pintière CT; Iero M; Rivoltini L; Baert-Desurmont S; Leprince J; Vaudry H; Sesboué R; Frébourg T; Latouche JB; Catros V
J Immunother; 2010 May; 33(4):402-13. PubMed ID: 20386466
[TBL] [Abstract][Full Text] [Related]
9. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
11. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
[TBL] [Abstract][Full Text] [Related]
12. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
14. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
[TBL] [Abstract][Full Text] [Related]
15. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
16. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
17. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
20. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
Moritz D; Groner B
Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
